Table 2_Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network.docx

Table 2_Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network.docx

Objective<p>To integrate pharmacovigilance and network pharmacology methods for a comprehensive analysis of the potential adverse reactions of complement C5 inhibitors (eculizumab, ravulizumab, zilucoplan) and neonatal Fc receptor (FcRn) inhibitors (efgartigimod, rozanolixizumab), and to explo...

Full description

Saved in:
Bibliographic Details
Main Author: Luqiong Wang (22389295) (author)
Other Authors: Jiaojiao Chen (6711764) (author), Huixiang Li (280714) (author), Lin Wang (11986) (author), Feiyu Liu (18291112) (author), Xiaoli Jiang (418410) (author)
Published: 2025
Subjects:
Genetic Immunology
FAERS database
adverse reactions
FcRn inhibitor
complement C5 inhibitor
eculizumab
ravulizumab
zilucoplan
efgartigimod
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items